AABB Publishes Summary of CY 2024 Hospital Opps Proposed Rule

AABB recently released a summary of the Centers for Medicare and Medicaid Services (CMS)’s final rule updating Medicare payment rates and policies under the hospital outpatient prospective payment system (OPPS) and the ambulatory surgical center payment system for calendar year (CY) 2024.

Each section of the summary document describes key provisions within the final rule related to the transfusion medicine and biotherapies community. These include payment policies and rates for transfusion medicine and cellular therapies and chimeric antigen receptor (CAR) T-cell therapy crosswalk mapping.

It also includes an update on the agency’s proposal to establish a separate payment to hospitals for maintaining access to a “buffer stock” of essential medicines under the Inpatient Prospective Payment System (IPPS). The blood community previously asked CMS to include blood and blood products as essential medicines and to ensure that the payments are sufficient to cover all costs associated with procuring and maintaining essential medicines.

Finally, the summary document features tables of payment rates for blood and blood products, as well as transfusion, apheresis and stem cell procedures.

Members with questions or feedback may contact advocacy@aabb.org.